-
-
-
-
-
-
-
Adicet Bio implements 1-for-16 reverse stock split effective Dec. 30
-
-
-
-
-
-
-
Adicet Bio reports initial lupus nephritis trial results
-
-
-
-
-
-
-
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Adicet Bio (ACET) Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
-
-
-
-
-
-
-
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
-
-
-
-
-
-
-
ACETO Corp (ACET) Reports In-Line Q3 EPS
-
-
-
-
-
-
-
Adicet Bio (ACET) Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
-
1,218,691 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

